Get access to our best features

Pfizer, BioNTech start COVID-flu combination vaccine study

Summary by Reuters
U.S. drugmaker Pfizer Inc (PFE.N) and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.
Published 3 months ago · New York, United States

News Articles

More Filters
All
Left
Center
Right

Pfizer-BioNTech to Test Combined Covid-19 And Flu Vaccine

The companies said in a statement the mRNA-based combination vaccine candidate was set to progress to a phase one trial in the United States with 180 volunteers

3 months ago·India
Read Full Article

Pfizer, BioNTech start COVID-flu combination vaccine study

U.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.

3 months ago·United Kingdom
Read Full Article

Pfizer starts early-stage trial of combined Covid and flu vaccine

The trial will look at the safety of the combined jab, how effective it is and whether patients suffer any side-effects

3 months ago·London, United Kingdom
Read Full Article

Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu

Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.

3 months ago·New Delhi, India
Read Full Article

Pfizer, BioNTech launch phase 1 trial on combined COVID-19 and flu vaccine

Pfizer and BioNTech announced Thursday that they have started a phase 1 trial on a combination COVID-19 and influenza vaccine.

3 months ago·United States
Read Full Article

Pfizer testing combined COVID, flu vaccine

Pfizer and BioNTech have launched a phase 1 trial for an mRNA-based vaccine that would target both COVID-19 and the influenza virus. According to BioNTech, the vaccine candidate is a combination of Pfizer’s flu vaccine candidate, which is in phase 3 clinical development, and the company’s bivalent omicron-specific coronavirus vaccine dose. The study includes 180…

3 months ago·Washington, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

55% of the sources are Center
The Independent
NDTV
abc News
GMA Filipino News
U.S. News
The Journal
+3
Reuters
The Hill
RTÉ
Channel News Asia
WION
Live Mint
+12
News18 India
Business Standard
Investor's Business Daily
Washington Examiner
The Blaze
Fox News
L 26%
C 55%
R 19%
See less detail